AIM ImmunoTech CEO and president Thomas K. Equels reports acquisition of $5,070.276 in common shares
AIM•AIM ImmunoTech CEO and President Thomas K. Equels purchased 31,298 common shares at $0.162 per share for $5,070.276, increasing his directly held shares to 254,095.
1. Share purchase
Thomas K. Equels purchased 31,298 AIM ImmunoTech common shares at $0.162 per share. The purchase increased his directly held common stock to 254,095 shares.
